10-Q: Gilead Q1 2026 Results and Strategic Acquisitions

Gilead Sciences reports Q1 2026 revenue of $6.96 billion and announces significant strategic acquisitions in oncology and immunology.

Summary

• Total revenue for Q1 2026 was $6.96 billion, a 4% increase compared to $6.67 billion in Q1 2025.
• Net income rose 54% to $2.02 billion, driven by net unrealized gains from equity securities and higher product sales.
• Diluted earnings per share (EPS) increased to $1.61 from $1.04 in the prior-year period.
• HIV product sales grew 10% to $5.03 billion, led by Biktarvy and Descovy.
• Oncology product sales increased 7% to $810 million, with Trodelvy sales up 37%.
• Veklury sales declined 52% to $144 million due to lower COVID-19 hospitalizations.
• The company completed the acquisition of Arcellx and announced agreements to acquire Tubulis and Ouro Medicines.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong core business growth and strategic expansion, though the significant upcoming acquisition-related charges temper the short-term financial outlook.

Positives

• Total revenue growth of 4% year-over-year.
• Strong performance in the HIV franchise, particularly Biktarvy (up 7%) and Descovy (up 38%).
• Trodelvy sales growth of 37% year-over-year.
• Net income increased significantly by 54% compared to Q1 2025.
• Product gross margin improved to 79.2% from 76.7%.

Negatives

• Veklury sales dropped 52% due to reduced COVID-19 demand.
• Cell Therapy product sales decreased 12% to $407 million.
• Selling, general and administrative expenses increased 15% to $1.45 billion.
• Royalty, contract and other revenues fell 75% to $14 million.

Risks

• Significant expected charges of approximately $11.5 billion in Q2 2026 related to recent acquisitions, leading to a projected net loss for the quarter and full year.
• Ongoing litigation and regulatory scrutiny, including antitrust class actions and product liability lawsuits.
• Impact of the Inflation Reduction Act (IRA) on pricing and reimbursement, specifically the selection of Biktarvy for Medicare price negotiation.
• Potential for 100% tariffs on patented pharmaceutical products and ingredients starting in the second half of 2026.
• Competitive headwinds in the Cell Therapy market.
• Risks associated with the integration of newly acquired companies and the success of their pipeline assets.

Future Outlook

Gilead expects to record approximately $11.5 billion in charges related to recent acquisitions in Q2 2026, which is expected to result in a net loss for both the second quarter and the full year 2026.

Management Comments

• Management remains committed to advancing innovative medicines to prevent and treat life-threatening diseases.
• The company is prioritizing investments in the business, R&D pipeline, and strategic partnerships to support long-term growth.

Industry Context

StockSavvy.ai notes that Gilead is aggressively pursuing inorganic growth through high-value acquisitions in oncology and immunology to offset the decline in COVID-19 related revenues and prepare for future patent cliffs. This strategy aligns with broader industry trends of large-cap biopharma companies utilizing strong balance sheets to acquire clinical-stage assets.

Comparison to Industry Standards

• Gilead's HIV franchise remains a dominant industry benchmark, maintaining strong growth despite competitive pressures.
• The company's shift toward oncology and cell therapy places it in direct competition with major players like Novartis, Bristol-Myers Squibb, and Johnson & Johnson.
• The significant acquisition-related charges are consistent with the high-cost environment for late-stage clinical assets in the current biotech M&A landscape.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing antitrust class action litigation related to HIV drugs.
• Product liability lawsuits involving Viread, Truvada, Atripla, Complera, and Stribild.
• Qui tam litigation regarding HCV and HIV sales practices.

Related Party Transactions

• Donation of equity securities to the Gilead Foundation, where certain officers serve as directors.

Stakeholder Impact

• Shareholders may see short-term volatility due to the projected net loss in 2026 resulting from acquisition charges.
• Patients may benefit from the expanded pipeline in oncology and autoimmune diseases.
• Employees may be impacted by ongoing restructuring and integration efforts.

Next Steps

• Integration of Arcellx, Tubulis, and Ouro Medicines.
• Continued development of BIC/LEN with a PDUFA date of August 27, 2026.
• Regulatory review of anito-cel with a PDUFA date of December 23, 2026.
• Ongoing management of legal proceedings and potential appellate outcomes.

Key Dates

Recommendation

While the core business is performing well, the massive $11.5 billion charge expected in Q2 2026 creates significant uncertainty for near-term earnings, warranting a cautious hold until the integration of new assets shows clear value creation.

Keywords

Gilead Sciences, Biopharmaceutical, HIV treatment, Oncology, Cell Therapy, Mergers and Acquisitions, Financial Results, Drug Pricing